H. B. Fuller (NYSE:FUL) Stock Passes Above Two Hundred Day Moving Average on Insider Selling
H. B. Fuller (NYSE:FUL) Stock Passes Above 200-Day Moving Average Following Insider Selling
Source link
Similar Posts
India to Maintain Investment Restriction on Bordering Nations – Equitypandit
October 23, 2024October 23, 2024 India will maintain its investment restrictions on neighbouring countries, the finance minister announced, just days after finalising an agreement with China on patrolling their disputed Himalayan border. This accord may mark the conclusion of a four-year military standoff and could improve strained political and…
Exploring Digital Equity With These 3 Stocks
This article was written by Follow I analyze securities based on value investing, an owner’s mindset, and a long-term horizon. I don’t write sell articles, as those are considered short theses, and I never recommend shorting.I was initially interested in a career in politics, but after reaching a dead-end in 2019 and seeing the financial…
AI evolution decoded: Ace investor Vijay Kedia explains it with a simple house-building analogy
How do you explain something as complex as artificial intelligence in the simplest way possible? Veteran stock market investor Vijay Kedia does it with a familiar idea, building a house. Start at the foundation. Imagine you have access to an expert whom you can ask anything about building a house. From design and materials to…
May 2nd COVID Update: COVID Deaths Continue to Decline
by Calculated Risk on 5/02/2025 07:56:00 PM Note: Mortgage rates are from MortgageNewsDaily.com and are for top tier scenarios. For deaths, I’m currently using 4 weeks ago for “now”, since the most recent three weeks will be revised significantly. Note: “Effective May 1, 2024, hospitals are no longer required to report COVID-19 hospital admissions, hospital…
Orchid Pharma Shares Shot Up 9% on DCGI Approval for UTI Treatment Drug – Equitypandit
Shares of Orchid Pharma Ltd shot-up 9% higher on 6 June after the company announced receiving approval from the Drugs Controller General of India (DCGI) to market the company’s antibiotic drug combination that is used for the treatment of complicated urinary tract infection (UTI). The company in its regulatory filing said that the DCGI has…
